Dentsply Sirona (NASDAQ:XRAY) misses Q3 2026 revenue estimates, stock drops 14.4%
Dentsply Sirona (XRAY) reported Q3 2026 revenue of $836M, missing estimates by 2.7% and down 7.5% YoY. Adjusted EPS was $0.29, missing estimates by 6.2%. Adjusted EBITDA beat estimates by 4.7%. The company lowered its full-year revenue and EPS guidance. Operating margin improved to 4.4%, while free cash flow margin dropped to 0%.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut are likely to trigger sell pressure, especially in the short term.
Market read
The report provides fresh, material information that can affect trading decisions on XRAY and related sector stocks.
What to watch
Operating margin improvement to 4.4% and a strong EBITDA beat may indicate underlying cost control.
Background
Dentsply Sirona is a leading dental equipment manufacturer listed on NASDAQ.
Ticker impact
Dentsply Sirona reported Q3 2026 revenue of $836M, missing estimates and cut full-year revenue guidance to $3.5B, causing a 14.4% stock drop.
likely further downside as investors price in weaker revenue outlook
Both revenue and EPS missed consensus and guidance was lowered, a clear bearish catalyst.
Market effects
Dental equipment sector may face broader scrutiny as peers' guidance could be re‑rated.
U.S. healthcare stocks could see modest pullback.
Limited to investors with exposure to dental and medical device markets.
Counterpoint
If the miss is viewed as a temporary setback and the company can improve margins, a bounce could be possible.
Key entities
- companyDentsply Sirona
Dental equipment manufacturer reporting Q3 2026 results.
